Mersana Therapeutics (MRSN) Receives “Buy” Rating from Cowen

Cowen restated their buy rating on shares of Mersana Therapeutics (NASDAQ:MRSN) in a research note released on Monday.

MRSN has been the subject of several other research reports. HC Wainwright set a $33.00 price target on shares of Mersana Therapeutics and gave the stock a buy rating in a research report on Friday, March 2nd. Zacks Investment Research upgraded shares of Mersana Therapeutics from a sell rating to a hold rating in a research report on Thursday, January 11th. JPMorgan Chase cut shares of Mersana Therapeutics from an overweight rating to a neutral rating and set a $23.00 price target for the company. in a research report on Monday, March 19th. ValuEngine upgraded shares of Mersana Therapeutics from a strong sell rating to a sell rating in a research report on Friday, February 2nd. Finally, Leerink Swann reiterated an outperform rating on shares of Mersana Therapeutics in a research report on Wednesday, March 28th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $24.80.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:MRSN opened at $16.81 on Monday. Mersana Therapeutics has a one year low of $12.45 and a one year high of $21.01.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Wednesday, March 28th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.13). The firm had revenue of $3.26 million for the quarter, compared to the consensus estimate of $4.22 million. equities analysts expect that Mersana Therapeutics will post -2.53 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Candriam Luxembourg S.C.A. acquired a new position in Mersana Therapeutics during the fourth quarter valued at approximately $197,000. ArrowMark Colorado Holdings LLC grew its holdings in Mersana Therapeutics by 88.4% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 899,773 shares of the company’s stock valued at $14,783,000 after purchasing an additional 422,062 shares during the period. Allianz Asset Management GmbH acquired a new position in Mersana Therapeutics during the third quarter valued at approximately $1,419,000. Victory Capital Management Inc. grew its holdings in Mersana Therapeutics by 11.0% during the fourth quarter. Victory Capital Management Inc. now owns 57,930 shares of the company’s stock valued at $952,000 after purchasing an additional 5,730 shares during the period. Finally, California State Teachers Retirement System acquired a new position in Mersana Therapeutics during the third quarter valued at approximately $142,000. Hedge funds and other institutional investors own 75.43% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Mersana Therapeutics (MRSN) Receives “Buy” Rating from Cowen” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2018/04/17/mersana-therapeutics-mrsn-receives-buy-rating-from-cowen.html.

About Mersana Therapeutics

Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.

Analyst Recommendations for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply